Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $17.33 Million Position in Pfizer Inc. (PFE)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Pfizer Inc. (NYSE:PFE) by 9.5% in the third quarter, HoldingsChannel reports. The firm owned 485,345 shares of the biopharmaceutical company’s stock after purchasing an additional 41,973 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Pfizer were worth $17,327,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of PFE. Municipal Employees Retirement System of Michigan raised its stake in Pfizer by 2.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 277,150 shares of the biopharmaceutical company’s stock valued at $9,309,000 after purchasing an additional 6,870 shares in the last quarter. John G Ullman & Associates Inc. raised its stake in Pfizer by 3.0% in the second quarter. John G Ullman & Associates Inc. now owns 466,336 shares of the biopharmaceutical company’s stock valued at $15,664,000 after purchasing an additional 13,494 shares in the last quarter. Longview Partners Guernsey LTD raised its stake in Pfizer by 6.9% in the second quarter. Longview Partners Guernsey LTD now owns 18,468,572 shares of the biopharmaceutical company’s stock valued at $620,359,000 after purchasing an additional 1,189,059 shares in the last quarter. Eastern Bank raised its stake in Pfizer by 1.4% in the second quarter. Eastern Bank now owns 146,336 shares of the biopharmaceutical company’s stock valued at $4,916,000 after purchasing an additional 1,969 shares in the last quarter. Finally, Boston Financial Mangement LLC raised its stake in Pfizer by 6.8% in the second quarter. Boston Financial Mangement LLC now owns 1,602,439 shares of the biopharmaceutical company’s stock valued at $53,826,000 after purchasing an additional 102,128 shares in the last quarter. 70.06% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.

A number of research analysts recently commented on PFE shares. BMO Capital Markets reaffirmed a “buy” rating and issued a $39.00 price target (up previously from $37.00) on shares of Pfizer in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, November 1st. UBS Group set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price for the company in a research note on Thursday, November 23rd. Finally, Deutsche Bank set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. Pfizer has a consensus rating of “Hold” and an average target price of $39.45.

Shares of Pfizer Inc. (NYSE PFE) opened at $34.66 on Tuesday. The firm has a market capitalization of $206,600.00, a PE ratio of 9.85, a PEG ratio of 1.93 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer Inc. has a twelve month low of $31.67 and a twelve month high of $39.43.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The company had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.47 earnings per share. research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer announced that its Board of Directors has approved a stock buyback plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.92%. The ex-dividend date is Thursday, February 1st. Pfizer’s payout ratio is 38.64%.

ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2018/02/13/commonwealth-of-pennsylvania-public-school-empls-retrmt-sys-has-17-33-million-position-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit